Skip to content
Storytelling Co – Lifestyle
Author:
Relay Therapeutics, Inc.
Relay Therapeutics Announces Data from Zovegalisib + Fulvestrant at the Phase 3 Dose of 400mg BID Fed at ESMO Targeted Anticancer Therapies Congress 2026
March 16, 2026
←
Previous Page
1
2